NexgenRx Inc. Stock

NXG

CA65337X1042

Investment Management & Fund Operators

Delayed Toronto S.E. Other stock markets 15:54:13 2026-07-03 EDT			5-day change	1st Jan Change
0.4800 ^CAD	+5.49%		+4.35%	+20.00%

05-22	Earnings Flash (NXG.V) NexgenRx Reported Q1 Total Revs $5.0M, Up 11.6% YoY; Net Income and EBITDA Improved	MT
05-21	NexgenRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

NexgenRx Inc. is a Canada-based independent full-service third-party administrator and technology solutions provider. The Company administers, adjudicates and pays drug, dental and other extended healthcare claims for the beneficiaries of health benefit plans underwritten by its customers, using proprietary computer software and also providing ancillary services. It offers plan sponsors, providers and patient support program/drug manufacturers a full suite of software-as-a-service solutions. The Companyâ€™s products include NexSys, NexAdmin, and NexPSPAssist. The NexSys is a fully integrated rules based adjudication platform for secure real-time processing of drug, dental and extended health benefit claims. Its NexAdmin product enables sponsors to take complete control of benefit plan administration. The NexPSPAssist service helps patient support programs (PSP) to optimize their deliverables to their manufacturer clients.

Employees

Sector

Investment Management & Fund Operators

More about the company

Quotes

Date	Price	Change	Volume
26-07-03	$0.4800	+5.49%	3,021
26-07-02	$0.4550	-1.09%	7,503
26-06-30	$0.4600	+2.22%	151,301

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

More financial data

Google lets you customize your preferred sources.

Choose MarketScreener

Market Cap	34.14M 24.07M 21.11M 19.49M 18.01M 2.3B 34.82M 234M 91.04M 1.13B 90.38M 88.4M 3.91B	P/E 2024	55x	P/E 2025	28.6x
Enterprise Value	29.73M 20.96M 18.38M 16.97M 15.68M 2.01B 30.32M 204M 79.27M 982M 78.7M 76.98M 3.41B	EV / Sales 2024	1.12x	EV / Sales 2025	1.34x
Free-Float	63.03%	Yield 2024	3.64%	Yield 2025	3.75%

05-22	Earnings Flash (NXG.V) NexgenRx Reported Q1 Total Revs $5.0M, Up 11.6% YoY; Net Income and EBITDA Improved	MT
05-21	NexgenRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-19	NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026	CI
03-31	NexgenRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-10	NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025	CI
11-21	NexgenRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-21	NexgenRx Q3 Revenue Rises 13%, Net Income and EBITDA Improve	MT
11-20	Earnings Flash (NXG.V) NexgenRx Reported Q3 Revenue $4.6M	MT
25-08-18	NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025	CI
25-08-12	NexgenRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-15	NexgenRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-17	Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025	CI
24-11-25	Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or Before December 20, 2024	CI

1 day	+5.49%
1 week	+4.35%
Current month	+4.35%
1 month	+5.49%
3 months	+33.33%
6 months	+26.32%
Current year	+20.00%

1 week	0.48	0.48
1 month	0.43	0.48
Current year	0.29	0.48
1 year	0.29	0.48
3 years	0.18	0.48
5 years	0.18	0.48
10 years	0.14	0.6

Manager	Title	Age	Since
Ronald Loucks CEO	Chief Executive Officer	-	2003-03-12
Phoebe Lee DFI	Director of Finance/CFO	-	-
Kelly Elher DFI	Director of Finance/CFO	63	2016-12-04

NexgenRx Inc. Stock

Stocks

NXG

CA65337X1042

Investment Management & Fund Operators

Valuation: NexgenRx Inc.

Chart: NexgenRx Inc.

Latest news : NexgenRx Inc.

Quotes and Performance

Course Extremes

Managers and Directors: NexgenRx Inc.

Latest insider transactions

Other Investment Management & Fund Operators

Financials

Company Profile

Quotes

Income Statement and Estimates

Director	Title	Age	Since
Ronald Loucks BRD	Director/Board Member	-	2003-03-12
Thomas Corcoran CHM	Chairman	-	2006-03-06
Charles Burns BRD	Director/Board Member	-	2017-06-15

Date	Insider	Type	Quantity	% Market Cap.
24-09-30	Paul Everett Crossett	Buy	14,500	0.0204%
24-09-16	Paul Everett Crossett	Buy	20,000	0.0281%
24-09-12	Paul Everett Crossett	Buy	15,000	0.0211%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEXGENRX INC.	+5.49%	+4.35%	+37.14%	+60.00%	24.07M
UBS GROUP AG	+2.10%	+2.24%	+47.83%	+136.98%	154B
BLACKROCK, INC.	+2.67%	+2.07%	-6.65%	+45.99%	153B
BANK OF NEW YORK MELLON CORPORATION (THE)	+3.13%	+5.42%	+66.12%	+250.43%	103B
BROOKFIELD CORPORATION	+1.30%	-0.02%	+7.86%	+114.59%	95.73B
BROOKFIELD ASSET MANAGEMENT LTD.	+2.70%	+1.64%	-13.55%	+57.54%	72.5B
STATE STREET CORPORATION	+3.05%	+7.14%	+67.16%	+145.46%	49.1B
AMERIPRISE FINANCIAL, INC.	+2.95%	+3.06%	-6.55%	+50.79%	44.1B
3I GROUP PLC	+2.00%	+2.55%	-36.52%	+41.69%	35.13B
NORTHERN TRUST CORPORATION	+2.65%	+4.68%	+45.48%	+150.58%	33.29B
Average	+2.77%	+2.92%	+20.83%	+105.41%	74.07B
Weighted average by Cap.	+2.41%	+2.84%	+21.85%	+114.76%

	2024	2025
Net sales	16.48M 11.62M 10.19M 9.41M 8.69M 1.11B 16.81M 113M 43.94M 544M 43.62M 42.67M 1.89B	17.93M 12.64M 11.09M 10.24M 9.46M 1.21B 18.29M 123M 47.82M 592M 47.48M 46.44M 2.06B
Net income	615K 433K 380K 351K 324K 41.49M 627K 4.22M 1.64M 20.3M 1.63M 1.59M 70.48M	1.29M 909K 798K 736K 680K 87.07M 1.32M 8.85M 3.44M 42.61M 3.41M 3.34M 148M
Net Debt	-1.17M -826K -725K -669K -618K -79.11M -1.2M -8.04M -3.12M -38.71M -3.1M -3.03M -134M	-4.41M -3.11M -2.73M -2.52M -2.33M -298M -4.5M -30.28M -11.76M -146M -11.68M -11.42M -506M